An Innovative Immunotoxin Design Against Allergy Based on the IL-33 Cytokine and the Ribotoxin α-Sarcin
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26199827 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Javier Narbona und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Faculty of Chemical Sciences, Complutense University, 28040 Madrid, Spain. Hauptthemen laut MEDLINE: Interleukin-33, Hypersensitivity, Immunotoxins, Ribonucleases. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia, Innovación y Universidades, Spanish Ministry of Science and Innovation, I+D+I Retos Investigación.
Abstract (Originalsprache)
Allergies constitute one of the major health problems worldwide, increasing their prevalence in developed countries. To overcome this multifactorial disease, immunotherapy and the use of immune molecules, such as immunotoxins, have arisen as promising therapeutic tools. We have designed, produced, and characterized a new immunotoxin called IL-33αS, encompassing the murine IL-33 (mIL-33) as the target domain and the ribotoxin α-sarcin as the toxic domain. IL-33 is a widely described alarmin that binds to the ST2 receptor of a variety of immune cells, including ILC2s, leading to Th2-derived inflammatory response, as occurs in allergic reactions. Both IL-33αS and mIL-33 were successfully produced in the methylotrophic yeast Pichia pastoris and purified to homogeneity through affinity chromatography for their characterization. Both IL-33αS and mIL-33 were able to specifically bind to ST2+ Raw 264.7 cells, and IL-33αS kept the ribonucleolytic activity of α-sarcin, allowing IL-33αS to exhibit cytotoxic effects against ST2+-targeted cells. In addition, IL-33αS induced significantly less secretion of the Th2-linked cytokine IL-13 in comparison to mIL-33, suggesting steric interference produced by the presence of the α-sarcin. These results assess the potential therapeutic effect of this new immunotoxin against allergies, causing ST2-targeted cytotoxicity while avoiding the Th2 cytokine secretion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, Faculty of Chemical Sciences, Complutense University, 28040 Madrid, Spain.
- Cancer Immunotherapy Unit, Immunology Department, Hospital Universitario 12 Octubre, Avda. de Córdoba, s/n, 28041 Madrid, Spain.
- Immuno-Oncology & Immunotherapy Group, Instituto Investigación Sanitaria 12 de Octubre, Avda. de Córdoba, s/n, 28041 Madrid, Spain.
- H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Centro Nacional de Investigaciones Oncológicas (CNIO), 28029 Madrid, Spain.
- Departamento de Ciencias Médicas Básicas, Facultad de Medicina, Instituto de Medicina Molecular Aplicada-Nemesio Díez (IMMA-ND), Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Ctra. Boadilla de…
ORCID-Profile: Javier Narbona, Juan Carlos López-Rodríguez, Mayte Villalba, Javier Lacadena
Förderung
- Ministerio de Ciencia, Innovación y Universidades
- Spanish Ministry of Science and Innovation, I+D+I Retos Investigación
Zitieren
APA
Narbona, J., Lázaro-Gorines, R., Gutiérrez-Carmona, A., López-Rodríguez, J. C., Villalba, M., & Lacadena, J. (2025). An Innovative Immunotoxin Design Against Allergy Based on the IL-33 Cytokine and the Ribotoxin α-Sarcin. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26199827
Vancouver
Narbona J, Lázaro-Gorines R, Gutiérrez-Carmona A, López-Rodríguez JC, Villalba M, Lacadena J. An Innovative Immunotoxin Design Against Allergy Based on the IL-33 Cytokine and the Ribotoxin α-Sarcin. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26199827
BibTeX
@article{Narbona2025,
author = {Narbona, Javier and Lázaro-Gorines, Rodrigo and Gutiérrez-Carmona, Adrián and López-Rodríguez, Juan Carlos and Villalba, Mayte and Lacadena, Javier},
title = {An Innovative Immunotoxin Design Against Allergy Based on the IL-33 Cytokine and the Ribotoxin α-Sarcin},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26199827}
}
EUVIMED